Deals in Depth: August 2008
August 2008 dealmaking highlights: excluding the $3.1 billion CSL/Talecris takeover, there was a weak showing in M&As across all industries in both the number of transactions done and total dollar value; and CSL's $1.5 billion private placement to support the acquisition was mainly responsible for the 75% showing in PIPE financings.
You may also be interested in...
While endocrine-disrupting evidence was inconclusive, the Scientific Committee on Consumer Safety recommends more conservative limits on use of homosalate, octocrylene and benzophenone-3 in cosmetic products compared with current requirements under the European Cosmetics Product Regulation.
The risk of inadvertently growing SARS-CoV-2 virus in cell and gene therapies and possibly infecting patients and workers should be assessed and mitigated, the agency advises.
Move was meant to preempt others’ efforts to secure the next six months of Regeneron’s COVID-19 antibody therapeutic.